Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Retained Earnings (2016 - 2025)

Altimmune (ALT) has disclosed Retained Earnings for 16 consecutive years, with -$622.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 12740.56% to -$622.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$622.1 million, a 12740.56% decrease, with the full-year FY2024 number at -$561.4 million, down 20.38% from a year prior.
  • Retained Earnings was -$622.1 million for Q3 2025 at Altimmune, down from -$603.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$4.8 million in Q3 2024 to a low of -$622.1 million in Q3 2025.
  • A 5-year average of -$257.6 million and a median of -$332.7 million in 2022 define the central range for Retained Earnings.
  • Biggest YoY gain for Retained Earnings was 98.98% in 2025; the steepest drop was 12740.56% in 2025.
  • Altimmune's Retained Earnings stood at -$5.0 million in 2021, then tumbled by 7397.7% to -$377.9 million in 2022, then fell by 23.41% to -$466.3 million in 2023, then dropped by 20.38% to -$561.4 million in 2024, then dropped by 10.82% to -$622.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Retained Earnings are -$622.1 million (Q3 2025), -$603.1 million (Q2 2025), and -$5.0 million (Q1 2025).